WEKO3
アイテム
{"_buckets": {"deposit": "b6a31b2f-7a63-4617-bb5d-8ce8b314df66"}, "_deposit": {"created_by": 2, "id": "5725", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "5725"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00005725", "sets": ["9"]}, "author_link": ["24580", "24576", "24574", "24579", "24578", "24577", "24575"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2014-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "9", "bibliographicPageEnd": "557", "bibliographicPageStart": "549", "bibliographicVolumeNumber": "20", "bibliographic_titles": [{"bibliographic_title": "Journal of Infection and Chemotherapy"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "We performed a postmarketing surveillance study to determine the efficacy and safety of the oral quinolone antibacterial agent, garenoxacin (Geninax R Tablets 200 mg), against bacterial pneumonia. Between October 2009 and March 2011, patients with community-acquired pneumonia visited 174 facilities in Japan; we collected survey forms from 739 patients of these patients who were suspected with bacterial pneumonia on the basis of factors, e.g., the presence of purulent sputum or suspected presence of bacterial pathogens in clinical specimens. We examined the safety in 730 patients and the efficacy in 535 patients. The efficacy rate of garenoxacin for bacterial pneumonia was 92.8% (479/516 patients). The eradication rates for Streptococcus pneumoniae and Haemophilus influenzae, the major pathogens of bacterial pneumonia, were 98.5% (65/66 strains) and 100% (65/65 strains), respectively. The incidence of adverse drug reactions (including abnormal laboratory tests) was 7.9% (58/730 patients). Among the main adverse drug reactions, abnormal laboratory tests were observed in 2.1% patients (15/730), hepatobiliary disorders were observed in 1.8% patients (13/730), and skin and subcutaneous tissue disorders were observed in 1.6% patients (12/730). In conclusion, garenoxacin showed an efficacy rate of greater than 90% for bacterial pneumonia and is considered to be useful in daily practice.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Journal of Infection and Chemotherapy, 20(9), pp.549-557; 2014", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "日本化学療法学会・日本感染症学会"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.jiac.2014.05.002", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2014, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved."}, {"subitem_rights": "NOTICE: this is the author’s version of a work that was accepted for publication in Journal of Infection and Chemotherapy. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Infection and Chemotherapy, 20, 9, (2014)"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1341321X", "subitem_source_identifier_type": "ISSN"}]}, "item_2_text_62": {"attribute_name": "出版者別言語", "attribute_value_mlt": [{"subitem_text_value": "Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Izumikawa, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "24574", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Watanabe, Akira"}], "nameIdentifiers": [{"nameIdentifier": "24575", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyashita, Naoyuki"}], "nameIdentifiers": [{"nameIdentifier": "24576", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishida, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "24577", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hosono, Hiroaki"}], "nameIdentifiers": [{"nameIdentifier": "24578", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kushimoto, Satoru"}], "nameIdentifiers": [{"nameIdentifier": "24579", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kohno, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "24580", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "JIC20_549.pdf", "filesize": [{"value": "439.0 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 439000.0, "url": {"label": "JIC20_549.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/5725/files/JIC20_549.pdf"}, "version_id": "9a9923d8-6f8b-400a-b1b9-68a6f91e1cdb"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Bacterial pneumonia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Clinical efficacy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Garenoxacin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Postmarketing surveillance", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Safety", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Efficacy and safety of garenoxacin tablets on bacterial pneumonia: Postmarketing surveillance in Japan", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Efficacy and safety of garenoxacin tablets on bacterial pneumonia: Postmarketing surveillance in Japan"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/34812", "pubdate": {"attribute_name": "公開日", "attribute_value": "2014-10-20"}, "publish_date": "2014-10-20", "publish_status": "0", "recid": "5725", "relation": {}, "relation_version_is_last": true, "title": ["Efficacy and safety of garenoxacin tablets on bacterial pneumonia: Postmarketing surveillance in Japan"], "weko_shared_id": -1}
Efficacy and safety of garenoxacin tablets on bacterial pneumonia: Postmarketing surveillance in Japan
http://hdl.handle.net/10069/34812
http://hdl.handle.net/10069/348124bc07101-f62b-410e-bffe-eb5f5c6ca4b4
名前 / ファイル | ライセンス | アクション |
---|---|---|
JIC20_549.pdf (439.0 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2014-10-20 | |||||
タイトル | ||||||
タイトル | Efficacy and safety of garenoxacin tablets on bacterial pneumonia: Postmarketing surveillance in Japan | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Bacterial pneumonia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Clinical efficacy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Garenoxacin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Postmarketing surveillance | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Safety | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Izumikawa, Koichi
× Izumikawa, Koichi× Watanabe, Akira× Miyashita, Naoyuki× Ishida, Tadashi× Hosono, Hiroaki× Kushimoto, Satoru× Kohno, Shigeru |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | We performed a postmarketing surveillance study to determine the efficacy and safety of the oral quinolone antibacterial agent, garenoxacin (Geninax R Tablets 200 mg), against bacterial pneumonia. Between October 2009 and March 2011, patients with community-acquired pneumonia visited 174 facilities in Japan; we collected survey forms from 739 patients of these patients who were suspected with bacterial pneumonia on the basis of factors, e.g., the presence of purulent sputum or suspected presence of bacterial pathogens in clinical specimens. We examined the safety in 730 patients and the efficacy in 535 patients. The efficacy rate of garenoxacin for bacterial pneumonia was 92.8% (479/516 patients). The eradication rates for Streptococcus pneumoniae and Haemophilus influenzae, the major pathogens of bacterial pneumonia, were 98.5% (65/66 strains) and 100% (65/65 strains), respectively. The incidence of adverse drug reactions (including abnormal laboratory tests) was 7.9% (58/730 patients). Among the main adverse drug reactions, abnormal laboratory tests were observed in 2.1% patients (15/730), hepatobiliary disorders were observed in 1.8% patients (13/730), and skin and subcutaneous tissue disorders were observed in 1.6% patients (12/730). In conclusion, garenoxacin showed an efficacy rate of greater than 90% for bacterial pneumonia and is considered to be useful in daily practice. | |||||
書誌情報 |
Journal of Infection and Chemotherapy 巻 20, 号 9, p. 549-557, 発行日 2014-09 |
|||||
出版者 | ||||||
出版者 | 日本化学療法学会・日本感染症学会 | |||||
出版者別言語 | ||||||
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases | ||||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1341321X | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.jiac.2014.05.002 | |||||
権利 | ||||||
権利情報 | c 2014, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. | |||||
権利 | ||||||
権利情報 | NOTICE: this is the author’s version of a work that was accepted for publication in Journal of Infection and Chemotherapy. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Infection and Chemotherapy, 20, 9, (2014) | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal of Infection and Chemotherapy, 20(9), pp.549-557; 2014 |